Picture EBD Group BioPharm America 2018 Boston September 600x60px
Document › Details

Medigene AG. (9/4/15). "Press Release: Medigene to Participate in Four International Conferences". Martinsried.

Organisations Organisation Medigene AG (MDG1, Frankfurt, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Baader Bank AG
  Group Baader Bank (Group)
Products Product Baader Investment Conference 2015 Munich
  Product 2 T cell therapy
Index term Index term Medigene–Baader Bank: investor conference, 201509 supply service Medigene presents at Baader Investment Conference 2015 in Munich
Person Person Hofmann, Julia (Medigene 201604 PR/IR)

Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in four upcoming investment and scientific conferences:

4th European Congress of Immunology

Date: 6 - 9 September 2015
Location: Vienna, Austria
Poster presentation on 9 September, 9:45 - 11:15 am (MEST): "Induction of memory T cell subpopulations for usage in adoptive T cell therapy" - Medigene's cooperation partner Helmholtz Zentrum Munich presents data generated in a joint SFB cooperation project.

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival

Date: 16 - 19 September 2015
Location: New York, USA
Poster presentation on 16 September, 7 - 9 pm (EDT): "Expitope: A webserver for TCR candidate validation"

HPV 2015 - 30th International Papillomavirus Conference

Date: 17 - 21 September 2015
Location: Lisbon, Portugal
Poster presentation on 18 - 20 September, 11:30 am - 1 pm (WEST): "Durable immunity to oncogenic HPV elicited by adjuvanted recombinant adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes"

Baader Investment Conference

Date: 22. - 24. September 2015
Location: Munich, Germany
Company presentation on 22 September, 12:15 pm (MEST)

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical and preclinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

Record changed: 2017-04-02


Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px

» top